ASP002 A Phase 2, multicenter, open-label extension study to evaluate the long-term safety and tolerability of rozanolixizumab in adult study participants with primary antiphospholipid syndrome.

Administered By

Awarded By

Contributors

Start/End

  • September 20, 2021 - October 14, 2023